Literature DB >> 6265682

Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice.

S M Shafie, F H Grantham.   

Abstract

The hormonal environments require by human breast cancer cells MCF-7 to produce solid tumors in nude mice are described. A 100% take was obtained within 7 days following inoculation of 2X10(6) actively growing (log phase) MCF-7 cells into the mammary fat pads of intact, athymic BALB/c nude mice. Tumors failed to develop, even with an inoculum of 20X10(6) cells/mouse, in ovariectomized mice or in mice made diabetic with streptozotocin and observed for 90 days after cell inoculation. A 100% incidence of tumors was obtained in mice that were either hypophysectomized or made diabetic but received injections of 0.2 IU insulin/day/mouse. A 100% incidence of tumors was also obtained in ovariectomized mice that received 17 beta-estradiol in the form of a pellet placed subcutaneously in the interscapular region at the time of cell inoculation. Palpable tumors also developed in ovariectomized mice treated with prolactin, perphenazine, estrone, or estriol, but no takes were observed in ovariectomized mice treated with progesterone, 5 alpha-dihydrotestosterone, or hydrocortisone. Growth of the MCF-7 tumor was stimulated five- to sixfold in both intact and hypophysectomized mice that each received a 17 beta-estradiol pellet. Removal of the 17 beta-estradiol pellets form tumor-bearing ovariectomized mice failed to induce tumor regression. Tumors that continued to grow in ovariectomized mice deprived of 17 beta-estradiol regressed by 50% or more of their initial volume when tamoxifen was injected for 7 days at 5 micrograms/mouse/day) +/- theophyline (1 mg/mouse/day), tumor growth arrest was observed during the 2-to 3-week treatment period. Streptozotocin-induced diabetes in tumor-bearing mice always resulted in complete tumor regression following a 3-week treatment period.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265682

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  42 in total

1.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Authors:  Danielle B Ulanet; Dale L Ludwig; C Ronald Kahn; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  Cell cycle expression of estrogen receptors determined by image analysis on human breast cancer cells in vitro and in vivo.

Authors:  P Rostagno; J L Moll; I Birtwisle-Peyrottes; F Ettore; C Caldani
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 3.  Long-term adjuvant tamoxifen therapy for breast cancer.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

4.  Tumor and serum tamoxifen concentrations in the athymic nude mouse.

Authors:  M W DeGregorio; E Coronado; C K Osborne
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  Obesity and cancer: at the crossroads of cellular metabolism and proliferation.

Authors:  Robert W O'Rourke
Journal:  Surg Obes Relat Dis       Date:  2014-08-27       Impact factor: 4.734

6.  Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.

Authors:  V Craig Jordan
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

7.  Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer.

Authors:  Teoman Coskun; Funda Kosova; Zeki Ari; Aslan Sakarya; Yavuz Kaya
Journal:  Mol Clin Oncol       Date:  2016-03-10

8.  Combined cytotoxic and endocrine therapy for human breast carcinoma (Br-10) serially transplanted into nude mice.

Authors:  T Kubota; K Kubouchi; J Koh; F Asanuma; K Enomoto; K Ishibiki; O Abe
Journal:  Jpn J Surg       Date:  1984-01

9.  Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.

Authors:  R Clarke; N Brünner; B S Katzenellenbogen; E W Thompson; M J Norman; C Koppi; S Paik; M E Lippman; R B Dickson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

10.  17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response.

Authors:  E C Chinje; K J Williams; B A Telfer; P J Wood; A J van der Kogel; I J Stratford
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.